v3.26.1
Revenue (Notes) - USD ($)
$ in Thousands
3 Months Ended
Apr. 05, 2026
Mar. 30, 2025
Disaggregation of Revenue [Line Items]    
Revenue from Contract with Customer [Text Block] Revenue
Disaggregation of revenue
Disaggregated revenue by primary geographical markets and major goods and service lines are as follows:
Reportable Segments
Three Months Ended
April 5, 2026March 30, 2025
Life SciencesDiagnosticsTotalLife SciencesDiagnosticsTotal
(In thousands)
Primary geographical markets
Americas$185,551 $130,441 $315,992 $184,279 $120,350 $304,629 
Europe91,695 131,351 223,046 76,022 105,770 181,792 
Asia84,599 87,481 172,080 80,094 98,247 178,341 
$361,845 $349,273 $711,118 $340,395 $324,367 $664,762 
Major goods/service lines
Life Sciences Solutions$299,996 $— $299,996 $286,453 $— $286,453 
Software61,849 — 61,849 53,942 — 53,942 
Immunodiagnostics— 201,831 201,831 — 197,562 197,562 
Reproductive Health— 147,442 147,442 — 126,805 126,805 
$361,845 $349,273 $711,118 $340,395 $324,367 $664,762 

Contract Balances
Unbilled receivable and Contract assets: The timing of revenue recognition may differ from the timing of customer billing. When revenue is recognized prior to billing and the right to the amount due from customers is conditioned only on the passage of time, the Company records an unbilled receivable on its consolidated balance sheets. Unbilled receivables totaled $106.7 million at April 5, 2026, of which $74.4 million was included in Accounts receivable, net and $32.3 million was included in Other assets, net in the condensed consolidated balance sheet. Unbilled receivables totaled $105.6 million at December 28, 2025, of which $72.4 million was included in Accounts receivable, net and $33.2 million was included in Other assets, net in the condensed consolidated balance sheet. Unbilled receivables primarily related to software revenue.The Company had no material contract assets as of April 5, 2026 and December 28, 2025.
Deferred revenue and Customer deposits: Deferred revenue is recorded when revenue is recognized subsequent to customer invoicing. Deferred revenue is classified as either current in “Accrued expenses and other current liabilities” or as long-term in “Deferred taxes and other long-term liabilities” in the condensed consolidated balance sheets based on the timing of when the Company expects to recognize revenue. The deferred revenue balance is primarily related to the Company’s software as a service offerings, maintenance contracts and prepaid storage arrangements. Deferred revenue totaled $238.5 million at April 5, 2026, of which $171.7 million was included in “Accrued expenses and other current liabilities” and $66.8 million was included in “Deferred taxes and other long-term liabilities” in the condensed consolidated balance sheet. Deferred revenue totaled $224.8 million at December 28, 2025, of which $159.3 million was included in “Accrued expenses and other current liabilities” and $65.5 million was included in “Deferred taxes and other long-term liabilities” in the condensed consolidated balance sheet. The Company also had customer deposits received in advance of the transfer of control totaling $20.3 million and $19.3 million at April 5, 2026 and December 28, 2025, respectively, which was included in “Accrued expenses and other current liabilities” in the condensed consolidated balance sheet. The Company expects that these customer deposits will be recognized in revenue within three months of the balance sheet date.
Transaction price allocated to the remaining performance obligations
The Company applies the practical expedient and does not disclose information about remaining performance obligations that have original expected durations of one year or less. The estimated revenue expected to be recognized in the future related to performance obligations that are unsatisfied (or partially unsatisfied) at the end of the period are not material to the Company. The remaining performance obligations primarily include noncancelable purchase orders, noncancelable software subscriptions and cloud service contracts and long-term prepaid storage contracts.
 
Segment revenue $ 711,118 $ 664,762
Americas [Member]    
Disaggregation of Revenue [Line Items]    
Segment revenue 315,992 304,629
Europe [Member]    
Disaggregation of Revenue [Line Items]    
Segment revenue 223,046 181,792
Asia [Member]    
Disaggregation of Revenue [Line Items]    
Segment revenue 172,080 178,341
Life Sciences Solutions [Member]    
Disaggregation of Revenue [Line Items]    
Segment revenue 299,996 286,453
Software [Member]    
Disaggregation of Revenue [Line Items]    
Segment revenue 61,849 53,942
Reproductive health [Member]    
Disaggregation of Revenue [Line Items]    
Segment revenue 147,442 126,805
Applied genomics [Member]    
Disaggregation of Revenue [Line Items]    
Segment revenue   664,762
Immunodiagnostics [Member]    
Disaggregation of Revenue [Line Items]    
Segment revenue 201,831 197,562
Diagnostics [Member]    
Disaggregation of Revenue [Line Items]    
Segment revenue 349,273 324,367
Diagnostics [Member] | Americas [Member]    
Disaggregation of Revenue [Line Items]    
Segment revenue 130,441 120,350
Diagnostics [Member] | Europe [Member]    
Disaggregation of Revenue [Line Items]    
Segment revenue 131,351 105,770
Diagnostics [Member] | Asia [Member]    
Disaggregation of Revenue [Line Items]    
Segment revenue 87,481 98,247
Diagnostics [Member] | Life Sciences Solutions [Member]    
Disaggregation of Revenue [Line Items]    
Segment revenue 0 0
Diagnostics [Member] | Software [Member]    
Disaggregation of Revenue [Line Items]    
Segment revenue 0 0
Diagnostics [Member] | Reproductive health [Member]    
Disaggregation of Revenue [Line Items]    
Segment revenue 147,442 126,805
Diagnostics [Member] | Immunodiagnostics [Member]    
Disaggregation of Revenue [Line Items]    
Segment revenue 201,831 197,562
Life Sciences [Member]    
Disaggregation of Revenue [Line Items]    
Segment revenue 361,845 340,395
Life Sciences [Member] | Americas [Member]    
Disaggregation of Revenue [Line Items]    
Segment revenue 185,551 184,279
Life Sciences [Member] | Europe [Member]    
Disaggregation of Revenue [Line Items]    
Segment revenue 91,695 76,022
Life Sciences [Member] | Asia [Member]    
Disaggregation of Revenue [Line Items]    
Segment revenue 84,599 80,094
Life Sciences [Member] | Life Sciences Solutions [Member]    
Disaggregation of Revenue [Line Items]    
Segment revenue 299,996 286,453
Life Sciences [Member] | Software [Member]    
Disaggregation of Revenue [Line Items]    
Segment revenue 61,849 53,942
Life Sciences [Member] | Reproductive health [Member]    
Disaggregation of Revenue [Line Items]    
Segment revenue 0 0
Life Sciences [Member] | Immunodiagnostics [Member]    
Disaggregation of Revenue [Line Items]    
Segment revenue $ 0 $ 0